Head and Neck Cancer Clinical Trials
Head and neck cancer clinical trials are important research studies designed to evaluate the effectiveness of promising new therapies in comparison to the currently available options. The goal is to find better ways to treat cancer – and ultimately find a cure – while enhancing patient quality of life. All new treatment options are evaluated in this way; in fact, the current standard of care was once available only through clinical trials.
Head and Neck Cancer Clinical Trials at Moffitt
As a recognized leader in performing groundbreaking cancer research, Moffitt Cancer Center has a nationally acclaimed clinical trials program with active protocols for various types of head and neck cancer. For instance, our researchers are studying:
- New surgical techniques
- New radiation delivery methods
- New chemotherapy drugs, drug combinations and dosages
- Emerging treatments, such as gene therapy
- New ways to prevent cancer recurrence
Patients who take part in clinical trials contribute to the existing knowledge base to help all current and future cancer patients and personally benefit by being closely monitored by a team of cancer experts as they receive either the current standard of care or new treatments that are unavailable elsewhere.
The End of Cancer Begins Here®
Find a Clinical TrialPatients who turn to Moffitt for head or neck cancer treatment can feel confident that they will receive the most effective treatment options available – whether or not they choose to participate in clinical trials. Our multispecialty team of experts emphasizes a bench-to-bedside approach, incorporating the latest laboratory findings into every patient’s unique treatment plan.
If you’d like to learn more about head and neck cancer clinical trials at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. No referrals are required.
-
Clinical Trials
CLINICAL TRIAL 17425
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Condition: Head & Neck
Intervention: Atezolizumab (Tecentriq); Cetuximab (); Erbitux (Cetuximab); Taxotere (docetaxel); cisplatin (); docetaxel ()
CLINICAL TRIAL 21131
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Condition: Head & Neck
Intervention: Paraplatin (carboplatin); Pembrolizumab (Keytruda); Radiotherapy (); carboplatin (); cisplatin ()
CLINICAL TRIAL 21641
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Condition: Head & Neck
Intervention: BCA101 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 21657
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Head & Neck
Intervention: Aloxi (Palonosetron); Aprepitant (); Dexamethasone (); Fosaprepitant (); Granisetron (); KCL (); Mannitol (); MgSO4 (); Olanzapine (); Ondansetron (); Palonosetron (); Zofran (Ondansetron); cisplatin ()
CLINICAL TRIAL 23229
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Condition: Multiple
Intervention: Lenti-HPV-07 ()
CLINICAL TRIAL 23298
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment Of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda); Placebo (); Zanzalintinib ()